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S
ince the dawn of the antimicrobial drug era, resistance
has shadowed the success of infectious disease therapy.
In his 1945 Nobel Prize acceptance speech, Alexander
Fleming noted the danger of resistance: “It is not difficult
to make microbes resistant to penicillin in the laboratory
by exposing them to concentrations not sufficient to kill
them, and the same thing has occasionally happened in the
body…. Moral: If you use penicillin, use enough” (1).
Sixty years later, our understanding of resistance has
grown vastly more sophisticated and the proliferation of
new antimicrobial drugs has engendered an equally varied
collection of resistance mechanisms (Figure). Resistance is
now an important problem in virtually all areas of
infectious diseases, including viral, bacterial, fungal, and
parasitic diseases. 
In a 2003 Institute of Medicine report, Microbial Threats
to Health, antimicrobial resistance was noted as a para-
mount microbial threat of the twenty-first century (2).
Some strains of pathogenic bacteria are now resistant to
essentially all available antimicrobial drugs, and some
remain susceptible to only one. At the same time, what once
was an apparent deluge of antimicrobial drug development
is now barely a trickle. The lack of new drug classes is a
consequence of difficulties in discovery of new compounds
that has persisted for many years. In addition, pharmaceuti-
cal companies are finding in industrialized nations more
potent markets for other disease treatments and lower
profit in nonindustrialized countries (3,4). This trend is
reflected in the absence of any novel class of antibacterial
drug approved for use in the United States between 1968
and 2000. Indeed, most of the new drugs approved since
1968 have been chemical modifications of existing drugs.
However, since 2000, two new drug classes have been
approved by the U.S. Food and Drug Administration (5,6).
Whether this trend will continue is unclear and does not
obviate the need for more new classes.
Barring the arrival in the near future of new antimicro-
bial drugs that are effective against disparate organisms,
we are left with imperfect tools to control drug resistance.
With a notable exception, vaccines have not been produced
that address the problem of resistance (7). Infection control
in healthcare settings, which is essential for preventing
transmission of susceptible and resistant microorganisms
alike, remains imperfect. Reducing the discretionary use of
antimicrobial drugs when possible is helpful, but even if
we use these drugs with exquisite precision, resistance will
continue to evolve and spread. Ensuring adherence to mul-
tidrug regimens to prevent emergence of resistance
requires uninterrupted drug supplies and is vulnerable to
human inconstancy. Finally, efforts to modify behavior
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Patrice Courvalin(sexual and otherwise), will always have limitations in a
free society. All of these shortcomings emphasize the crit-
ical role of research and dissemination of information. For
that reason, this issue of Emerging Infectious Diseases is
devoted to antimicrobial resistance and highlights both
burgeoning and neglected areas. 
Articles address antimicrobial resistance in pathogens
from the community, healthcare settings, and agriculture,
among children and adults, and in several countries. In the
case of community-associated methicillin-resistant
Staphylococcus aureus (MRSA), articles cover outbreaks
in Uruguay and in a US hospital nursery and maternity
unit, emergence of a particular clone in Canada, preva-
lence in US emergency department patients, characteristics
of patients admitted to a Swiss hospital, and the severity of
this infection in pediatric patients. One article estimates
hospitalizations associated with MRSA infection. These
articles show some of the changing spectrum of disease
and populations affected by this pathogen. The success of
a relatively new vaccine against resistant Streptococcus
pneumoniae and its impact on resistant infections is
described. Resistance towards macrolides and structurally
related drugs is the subject of several articles.
Antimicrobial-resistant foodborne infections are addressed
in articles on Salmonella spp. and Campylobacter jejuni.
Several articles discuss resistant organisms that are largely
problems in healthcare settings or among persons with
underlying illness, such as extended-spectrum β-lactamase
(ESBL) producing Escherichia coli, vancomycin-resistant
Enterococcus faecium, and gram-negative bacilli.
Multidrug-resistant tuberculosis, perennially transmitted
inside and outside healthcare and other institutional set-
tings, is also discussed in 2 articles. An article on
Trypanosoma brucei gambiense describes the importance
and difficulty in determining resistance in parasitic infec-
tions, which can have countrywide implications for treat-
ment, control, and use of resources.
This issue does not cover resistance in malaria, gonor-
rhea, and HIV infection. An estimated 300–500 million
clinical cases of malaria occur each year, and resistance
exists to some extent to nearly all available antimalarial
drugs. Efforts are under way to produce new drugs, but one
of the most efficacious candidates has run into economic
and manufacturing obstacles (8,9). Gonorrhea treatment
and control are becoming increasingly difficult because of
increases in resistance to multiple classes of drugs and the
discontinued production of a preferred oral medication
(10,11). Antiretroviral drug resistance has been well
demonstrated in countries in which the standard of care
mandates treatment of HIV-infected persons. The immi-
nent widespread use of antiretroviral drugs in countries
with large populations infected with HIV, but for whom
treatment has not been provided, will carry with it the
specter of global resistance, thereby threatening the intend-
ed benefits (12). Finally, in the absence of vaccine, the
long-anticipated arrival of a global influenza pandemic,
caused by H5N1 or another strain, would have potentially
devastating consequences with respect to resistance. The
potential for antiviral drug resistance to develop during
treatment is manifest. The likely increased use of oral anti-
bacterial drugs for patients with possible influenza and for
prophylaxis and treatment of secondary bacterial pneumo-
nia would enhance the existing evolutionary pressure
toward resistance. The predictably large numbers of sec-
ondary bacterial pneumonias may be caused by established
resistant pathogens (e.g., pneumococcus) and emerging
ones (e.g., community-associated MRSA).
Fleming’s warning about inappropriate use has reso-
nance today. Several articles describe the importance of
the appropriate use of antimicrobial drugs as well as the
difficultly of enforcement. The hope of preserving the
effectiveness of existing drugs through appropriate use as
well as the urgent need for the development of new drugs
are both represented by the artwork featured on the cover
of this issue. We hope to promote greater awareness among
our readers of the strong link between antimicrobial drug
use and the development of resistance and to make clear
that improving use in community, healthcare, and agricul-
ture settings, combined with other strategies, is imperative
if we are to confront effectively the further development
and spread of antimicrobial resistance.
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